Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Catrix is a brand name associated with three distinct pharmaceutical products. One formulation is an oral tablet containing **aceclofenac**, a non-steroidal anti-inflammatory drug (NSAID) that preferentially inhibits cyclooxygenase-2 (COX-2) to treat pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. A second product is a topical **bovine cartilage powder** used as a biological dressing for wound healing in pressure ulcers, venous stasis ulcers, diabetic ulcers, and burns; it promotes healing by stimulating the growth of fibroblasts and keratinocytes. A third version is an **ophthalmic solution** containing anhydrous sodium succinate and cytochrome C, developed by Incepta Pharmaceuticals for the treatment of lens opacification (cataracts) by supporting cellular metabolism and providing antioxidant effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Catrix.